# Cefixime for Alternative Syphilis Treatment

> **NCT03660488** · PHASE2 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 58 (actual)

## Conditions studied

- Syphilis
- Early Syphilis

## Interventions

- **DRUG:** Cefixime 400 milligram Oral Capsule [Suprax]
- **DRUG:** Benzathine Penicillin G

## Key facts

- **NCT ID:** NCT03660488
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-03
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-01-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660488, "Cefixime for Alternative Syphilis Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03660488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*